Evidence map›Paper›PMID 24932614›Full record

Observational studyAIDS (London, England)2014

Antiretroviral therapy modifies the genetic effect of known type 2 diabetes-associated risk variants in HIV-infected women.

Melissa A Frasco, Roksana Karim, David Van Den Berg, Richard M Watanabe, Kathryn Anastos, Mardge Cohen, Stephen J Gange, Deborah R Gustafson, Chenglong Liu, Phyllis C Tien and 2 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in AIDS (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Melissa A FrascoaDepartment of Preventive Medicine, University of Southern California bDepartment of Physiology and Biophysics University of Southern California cUSC Diabetes and Obesity Research Institute, University of Southern California, Los Angeles, California dMontefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York eStroger Hospital and Rush University, Chicago, Illinois fJohns Hopkins Bloomberg School of Public Health, Baltimore, Maryland gState University New York - Downstate Medical Center, Brooklyn, New York hGeorgetown University School of Medicine, District of Columbia iUniversity of California San Francisco jDepartment of Veterans Affairs, San Francisco, California, USA. *Wendy J. Mack and Celeste Leigh Pearce contributed equally to the writing of this article.
Roksana Karim
David Van Den Berg
Richard M Watanabe
Kathryn Anastos
Mardge Cohen
Stephen J Gange
Deborah R Gustafson
Chenglong Liu
Phyllis C Tien
Wendy J Mack
Celeste L Pearce
University of Southern California · USGeorgetown University · USJohns Hopkins University · USMontefiore Medical Center · USRush University · USSan Francisco VA Medical Center · USSUNY Downstate Health Sciences University · US

Funding

UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1-TR000004NCRR NIH HHS UL1 RR024131NIAID NIH HHS U01 AI031834NIAID NIH HHS U01-AI-031834NIAID NIH HHS U01-AI-034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01-AI-034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01-AI-034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01-AI-035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-042590NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD-032632
6 · The paper itself

Abstract

objectiveType 2 diabetes mellitus incidence is increased in HIV-infected persons. We examined the associations of diabetes mellitus with known diabetes mellitus-risk alleles from the general population in the context of HIV infection, and explored effect modification by combination antiretroviral therapy (cART).

methodsThe Women's Interagency HIV Study is a prospective cohort of HIV-infected women. Seventeen European-derived diabetes mellitus-risk polymorphisms were genotyped in the eligible participants of the Women's Interagency HIV Study. Analyses were run separately for non-African Americans (Whites, Hispanics, Asians, and other; n = 378, 49 with incident diabetes mellitus) and African Americans (n = 591, 49 with incident diabetes mellitus). Cox proportional-hazards models were fit to estimate hazard ratios for diabetes mellitus overall and within strata of cART.

resultsIn non-African Americans, heterogeneity across cART regimen was observed for nine of the 14 polymorphisms (phet < 0.05). One polymorphism was statistically significantly inversely associated with diabetes mellitus risk among women taking two nucleotide reverse transcriptase inhibitors (NRTIs) + non-nucleotide reverse transcriptase inhibitor (NNRTI). Five polymorphisms were statistically significantly associated with diabetes mellitus among women treated with at least two NRTIs + at least one protease inhibitor and one polymorphism was associated with diabetes mellitus among those treated with at least three NRTIs ± NNRTI. The hazard ratio per risk allele for IGF2BP2 rs1470579 was 2.67 (95% confidence interval 1.67-4.31) for women taking cART with at least two NRTIs + at least one protease inhibitor and 2.45 (95% confidence interval 1.08-5.53) in women taking at least three NRTIs ± NNRTI (phet = 2.50 × 10⁻³). No such associations were observed in the African Americans.

conclusionsGenetic susceptibility to diabetes mellitus, based on the variants studied, is substantially elevated among HIV-infected women using cART containing three or more NRTI/protease inhibitor components. A personalized medicine approach to cART selection may be indicated for HIV-infected persons carrying these diabetes mellitus-risk variants.

Indexed as

Genetic Predisposition to DiseaseAdolescentAdultAgedAged, 80 and overAnti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCohort StudiesDiabetes Mellitus, Type 2EthnicityFemaleHIV InfectionsHumansMiddle AgedProspective StudiesRisk AssessmentAnti-Retroviral Agents

Identifiers

PMID24932614
PMCPMC4269472
OpenAlexW2322362667

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.